Abstract
The National Blood Service has undertaken a strategic review of Nucleic acid Amplification Technology (NAT) Testing used to screen blood for Hepatitis C Virus (HCV) at the request of the Department of Health.Three strategic options have been considered and are presented within this review:Continue testing (which in practice also includes developing this technology further as new automated platforms and multiplex tests become available).Substitute HCV antigen testing for NAT testingStop NAT HCV testingIn essence, this review concludes that NAT HCV testing is an extremely expensive intervention. Now that NAT testing is well developed by Blood Services world‐wide and has been in use to screen the UK population for some time, the consequences of pursuing each of the options presented can be predicted with accuracy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
